Gerresheimer’s shares have roared back roughly 50% from their 52-week low, but the rally has a fragile look. Behind the price action lies a tangle of unresolved accounting discrepancies, regulatory investigations, and a heavily shorted stock that leaves every upward move vulnerable to sudden reversals.
The stock closed Tuesday at €28.45, only to fall back 6.8% on Wednesday to €26.38, according to one data feed, while another source pegged the same session at €26.50. The 30-day performance still shows a 51.08% gain on that latter close, yet over 12 months the shares have lost 57.29% — a stark reminder of how much trust has been eroded. The relative strength index had pushed above 71 before the pullback, signaling overbought conditions that invited profit-taking.
Short sellers retain a firm grip
Short interest stands at roughly 11.4%, well above the company’s 12-month average. Although Arrowstreet Capital trimmed its short position slightly, Millennium International Management increased its bet against the stock. The result is that any relief rally meets persistent selling pressure from hedge funds betting on further downside.
That dynamic has been amplified by a wave of short-covering that helped fuel the initial recovery. But with more than one in ten free-float shares still borrowed and sold, the market is far from convinced the worst is over.
Accounting probes widen
The real stress lies in Gerresheimer’s books. A second external audit firm is now reviewing prior-year accounts, delaying the release of the audited 2025 financial statements until June 2026. The delay has opened the door to multiple scrutiny channels.
Germany’s financial regulator BaFin expanded its investigation in March, adding fresh concerns to the probe first launched in September 2025. Separately, the auditor oversight body APAS is examining KPMG’s work, after the firm gave an unqualified opinion on the 2024 accounts that included €35 million in bill-and-hold transactions now under dispute.
The numbers being questioned are material:
– €65.5 million in potentially misstated lease liabilities
– €29.4 million in incorrectly capitalized development costs
– €196.5 million in assets tied to the Advanced Technologies segment
Should investors sell immediately? Or is it worth buying Gerresheimer?
These items could reshape how investors view Gerresheimer’s leverage, profitability, and overall balance-sheet quality.
Creditors offer breathing room
Lenders have stepped in to buy time. Schuldschein holders representing 96% of the total outstanding volume agreed to extend covenant deadlines to the end of September 2026. Banks also waived key leverage-based credit conditions through the third quarter. The reprieve gives management space to complete the audit and push ahead with a planned asset sale.
That sale centers on the US subsidiary Centor Inc. Morgan Stanley has been hired to run the process. The division was valued at €292 million on the books at the end of 2024. According to the company, a double-digit number of suitors have already entered the process, with a deal penciled in for 2026. The proceeds are meant to reduce debt taken on after the Bormioli acquisition, though a sale alone won’t automatically fix the underlying accounting questions.
Operational forecast holds — for now
Management has maintained its 2026 guidance: revenue of €2.3 to €2.4 billion and an adjusted EBITDA margin of 18% to 19%. In a climate where the market is laser-focused on balance-sheet resilience rather than growth, those numbers are crucial to keep the story alive.
The next hard deadline is the publication of the audited annual and consolidated accounts in June 2026, followed shortly by the first-quarter trading update. The half-year report is scheduled for July 14. The annual general meeting, initially planned for late in the second quarter, remains postponed until the audit is complete.
Until then, Gerresheimer’s stock is trapped between a speculative rally and a calendar of potential landmines. Any fresh accounting revelation could trigger a new wave of short selling. A clean audit, by contrast, could lay the groundwork for a genuine re-rating. For now, the biggest unknown is whether the surge in the share price is a recovery — or a reprieve.
Ad
Gerresheimer Stock: Buy or Sell?! New Gerresheimer Analysis from May 14 delivers the answer:
The latest Gerresheimer figures speak for themselves: Urgent action needed for Gerresheimer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from May 14.
Gerresheimer: Buy or sell? Read more here...
